U.S. FDA Grants Priority Review of ZYTIGA® (Abiraterone Acetate) sNDA for …

Published August 30, 2012

U.S. FDA Grants Priority Review of ZYTIGA® (abiraterone acetate) sNDA for …

Filed under: drug treatment news 2012

29, 2012 — /PRNewswire/ — Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA® (abiraterone acetate) … "We …
Read more on Sacramento Bee

ArQule says partner halts cancer drug trial, shares slide

Filed under: drug treatment news 2012

The trial was investigating the use of ArQule's drug, tivantinib, in combination with Roche Holding AG's FDA-approved drug Tarceva, generically known as erlotinib, compared with a combination of erlotinib and placebo, to treat patients with non …
Read more on Reuters

From Twitter:

http://t.co/99mz50fT Tuberculosis Drug Combo Cut Treatment Time in Study – Bloomberg: Family Practice News Digita… http://t.co/jUroOCWT – by bombaygold (Admn)

From Twitter:

Ancient killer turning untreatable once more http://t.co/wjvxmcND via @BloombergNews @maki_kitamura – by jwgale (Jason Gale)

From Twitter:

Tuberculosis Drug Combo Cut Treatment Time in Study – Bloomberg: Family Practice News Digital NetworkTuberculosi… http://t.co/SCoKPotG – by 1sthealthnews (Breaking Health News)